The publication of the first three EU Joint Clinical Assessments (JCAs) provides the first opportunity to evaluate how the EU HTA Regulation is being applied in practice. While each assessment is product-specific, together they reveal consistent themes around evidence expectations, methodological scrutiny and the level of documentation required to support future submissions.
This analysis reviews the first three published JCAs to identify the emerging patterns shaping future assessments. It examines how assessors are evaluating comparative evidence, uncertainty and methodological robustness, and highlights the practical implications for evidence generation, pricing and market access planning.
Download the Analysis
What the analysis covers
- Key learnings emerging across the first three published EU Joint Clinical Assessments.
- How assessors are evaluating comparative evidence, indirect treatment comparisons and methodological robustness.
- Common evidence gaps, documentation requirements and areas of scrutiny identified across the early assessments.
- Practical implications for evidence generation, pricing and market access strategy.
- Strategic considerations for manufacturers preparing future JCA submissions.